HGEN Stock Price, Humanigen, Inc. Quote, Chart

Market Summary

USD57.40+0.40

Market Closed

0.70%

HGEN Stock Price

View Fullscreen

HGEN RSI Chart

HGEN Valuation

EV/EBITDA

-1.8K

HGEN Price/Sales (Trailing)

HGEN Profitability

HGEN Fundamentals

HGEN Revenue

HGEN Earnings

Breaking Down HGEN Revenue

Last 7 days

0.9%

Last 30 days

30.5%

Trailing 12 Months

38166.7%

How does HGEN drawdown profile look like?

HGEN Financial Health

HGEN Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.7M	0	0	0
2022	4.1M	4.1M	3.3M	2.5M
2021	1.1M	2.0M	2.8M	3.6M
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	0
2016	0	0	0	0
2015	0	0	0	29.0K
2013	4.6M	3.1M	1.6M	44.0K
2012	19.0M	17.7M	11.9M	6.1M
2011	18.3M	19.0M	19.6M	20.3M
2010	0	0	0	17.7M
2009	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Humanigen, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 18, 2023	chappell dale	sold	-376	0.011	-34,253	chief scientific officer
Oct 18, 2023	chappell dale	sold	-834	0.011	-75,887	chief scientific officer
Oct 18, 2023	chappell dale	sold	-3,038	0.011	-276,210	chief scientific officer
May 20, 2022	chappell dale	bought	243,070	2.228	109,098	chief scientific officer
May 20, 2022	chappell dale	bought	850,742	2.228	381,841	chief scientific officer
May 20, 2022	chappell dale	bought	121,535	2.228	54,549	chief scientific officer
May 19, 2022	chappell dale	bought	70,784	2.186	32,381	chief scientific officer
May 19, 2022	chappell dale	bought	141,570	2.186	64,762	chief scientific officer
May 19, 2022	chappell dale	bought	495,490	2.186	226,665	chief scientific officer
May 18, 2022	chappell dale	bought	34,079	1.962	17,370	chief scientific officer

Which funds bought or sold HGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Triumph Capital Management	unchanged	-	-17.00	3.00	-%
Feb 14, 2023	Telemetry Investments, L.L.C.	reduced	-6.00	-34,000	56,000	0.09%
Nov 14, 2022	Corient Capital Partners, LLC	unchanged	-	-	19,000	-%
Aug 15, 2022	Frontier Wealth Management LLC	unchanged	-	-47,000	108,000	0.01%
May 16, 2022	Amalgamated Financial Corp.	new	-	24,000	24,000	-%
May 16, 2022	Parametric Portfolio Associates LLC	new	-	92,000	92,000	-%
Nov 15, 2021	Marshall Wace North America L.P.	sold off	-100	-3,891,000	-	-%

Are Funds Buying or Selling HGEN?

Are funds buying HGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HGEN

No. of Funds

Unveiling Humanigen, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 01, 2023	murchinson ltd.	0.00%	0	SC 13G/A
May 09, 2022	blackrock inc.	4.7%	3,322,546	SC 13G
Mar 17, 2022	cheval holdings, ltd.	1.7%	1,117,989	SC 13D/A
Feb 14, 2022	valiant capital management, l.p.	10.8%	6,888,607	SC 13G/A
Feb 04, 2022	blackrock inc.	5.2%	3,343,800	SC 13G
Jan 10, 2022	state street corp	1.48%	946,577	SC 13G/A
Dec 30, 2021	murchinson ltd.	7.02%	4,476,884	SC 13G
Oct 12, 2021	state street corp	14.82%	8,801,491	SC 13G
Aug 30, 2021	nomis bay ltd.	-	12	SC 13D/A
Jul 20, 2021	cheval holdings, ltd.	1.5%	910,686	SC 13G/A

Peers (Alternatives to Humanigen, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Humanigen, Inc. News

Latest updates

Humanigen, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	0%	221,000	221,000	221,000	1,036,000	1,036,000	1,037,000	1,036,000	1,036,000	486,000	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	209.3%	4,456,000	-4,076,000	22,942,000	30,387,000	21,565,000	33,382,000	67,015,000	71,088,000	64,882,000	32,607,000	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	12.7%	3,719,000	3,301,000	4,013,000	3,949,000	4,345,000	4,024,000	6,204,000	8,076,000	4,948,000	4,112,000	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	110.0%	737,000	-7,377,000	18,929,000	26,438,000	17,220,000	29,358,000	60,811,000	63,012,000	59,934,000	28,495,000	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-102.3%	-0.01	0.28	0.40	0.19	0.18	0.01	-0.25	-0.74	-1.12	-2.81	-18.31	-6.59	-	-	-	-	-	-	-	-	-
Interest Expenses	-84.7%	18,000	118,000	1,298,000	768,000	734,000	748,000	751,000	746,000	19,000	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-48.0%	-1.31	-0.89	-0.67	-0.54	-0.54	-0.62	-0.80	-1.14	-1.97	-7.15	-76.97	-76.97	-	-	-	-	-	-	-	-	-
Net Income	-195.3%	-4,182,000	4,390,000	-23,693,000	-30,149,000	-21,278,000	-33,540,000	-66,739,000	-70,803,000	-65,567,000	-32,295,000	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-12.2%	-31.57	-28.13	-32.63	-36.60	-46.41	-65.83	-84.85	-102	-134	-286	-2,043	-1,065	-	-	-	-	-	-	-	-	-
Free Cashflow	51.6%	-7,059,000	-14,570,000	-17,309,000	-25,377,000	-19,442,000	-32,259,000	-48,002,000	-67,960,000	-35,824,000	-23,695,000	-23,543,000	-22,007,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Assets	-54.3%	5.00	11.00	26.00	49.00	71.00	71.00	78.00	122	99.00	68.00	92.00	43.00	29.00	15.00	1.00	2.00	1.00	1.00	3.00	1.00	3.00
Current Assets	-54.7%	5.00	11.00	26.00	49.00	71.00	71.00	78.00	122	99.00	68.00	92.00	42.00	0.00	0.00	1.00	2.00	1.00	1.00	3.00	1.00	2.00
Cash Equivalents	-69.5%	3.00	10.00	25.00	47.00	69.00	70.00	77.00	121	93.00	68.00	91.00	42.00	0.00	0.00	0.00	1.00	0.00	1.00	2.00	0.00	2.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00
Liabilities	-5.4%	55.00	58.00	78.00	100	96.00	95.00	96.00	78.00	82.00	23.00	15.00	11.00	17.00	15.00	13.00	12.00	10.00	9.00	9.00	8.00	8.00
Current Liabilities	-5.2%	53.00	56.00	76.00	77.00	71.00	69.00	69.00	50.00	53.00	20.00	15.00	11.00	15.00	14.00	10.00	10.00	9.00	8.00	8.00	8.00	7.00
Long Term Debt	-	-	-	-	23.00	25.00	25.00	25.00	25.00	24.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	23.00	25.00	25.00	25.00	25.00	24.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-	-	-	-	-	-	-	-	44.00	17.00	46.00	77.00	32.00	-	-	-	-	-	-	-	-	-
Retained Earnings	-0.6%	-685	-681	-686	-662	-632	-611	-577	-510	-440	-374	-342	-311	-287	-284	-282	-280	-277	-274	-272	-270	-267
Additional Paid-In Capital	0.2%	636	635	634	612	607	587	560	554	457	420	419	343	271	271	270	270	267	266	266	263	262
Shares Outstanding	0%	119	119	119	71.00	66.00	64.00	59.00	56.00	53.00	52.00	32.00	27.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	84.00	-	-	-	711	-	-	-	370	-	-	-	48.00	-	-	-	28.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Cashflow From Operations	51.6%	-7,059	-14,570	-17,309	-25,377	-19,442	-32,259	-48,002	-67,960	-35,824	-23,695	-23,543	-22,007	-607	-549	-1,179	-1,589	-684	-1,224	-1,254	-1,903	-1,828
Share Based Compensation	-2.2%	1,222	1,250	1,382	1,635	1,543	1,553	1,434	1,871	510	476	1,012	357	265	148	451	729	697	642	715	780	2,675
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	-	-	-	-5,012	3,475	18,374	25,775	3,966	95,604	60,979	1.00	73,265	63,668	532	535	245	2,500	50.00	-	3,025	580	2,651

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HGEN Income Statement

2023-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 221	$ 1,036
Operating expenses:
Research and development	737	17,220
General and administrative	3,719	4,345
Total operating expenses	4,456	21,565
Loss from operations	(4,235)	(20,529)
Other income (expense):
Interest expense	(18)	(734)
Other income (expense), net	71	(15)
Net loss	$ (4,182)	$ (21,278)
Basic net loss per common share (in Dollars per share)	$ (0.04)	$ (0.32)
Weighted average common shares outstanding used to calculate basic net loss per common share (in Shares)	119,080,135	65,590,724
License revenue
Revenue:
Total revenue	$ 221	$ 1,036

HGEN Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,096	$ 10,155
Prepaid expenses and other current assets	1,930	950
Total current assets	5,026	11,105
Other assets	90	90
Total assets	5,116	11,195
Current liabilities:
Accounts payable	38,392	40,520
Accrued expenses	14,021	14,791
Deferred revenue	883	883
Total current liabilities	53,296	56,194
Non-current liabilities:
Deferred revenue	1,545	1,766
Total liabilities	54,841	57,960
Stockholders’ deficit:
Common stock, $0.001 par value: 225,000,000 shares authorized at March 31, 2023 and December 31, 2022; 119,080,135 shares issued and outstanding at March 31, 2023 and December 31, 2022	119	119
Additional paid-in capital	636,147	634,925
Accumulated deficit	(685,991)	(681,809)
Total stockholders’ deficit	(49,725)	(46,765)
Total liabilities and stockholders’ deficit	$ 5,116	$ 11,195

About Humanigen, Inc.

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

CEO	Dr. Cameron Durrant M.D., MBA
WEBSITE	humanigen.com
INDUSTRY	Biotechnology
EMPLOYEES	6

Humanigen, Inc. Frequently Asked Questions

What is the ticker symbol for Humanigen, Inc.? What does HGEN stand for in stocks?

HGEN is the stock ticker symbol of Humanigen, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Humanigen, Inc. (HGEN)?

As of Fri May 17 2024, market cap of Humanigen, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HGEN stock?

You can check HGEN's fair value in chart for subscribers.

What is the fair value of HGEN stock?

You can check HGEN's fair value in chart for subscribers. The fair value of Humanigen, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Humanigen, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Humanigen, Inc. a good stock to buy?

The fair value guage provides a quick view whether HGEN is over valued or under valued. Whether Humanigen, Inc. is cheap or expensive depends on the assumptions which impact Humanigen, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HGEN.

What is Humanigen, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HGEN's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Humanigen, Inc.'s stock?

In the past 10 years, Humanigen, Inc. has provided 0.149 (multiply by 100 for percentage) rate of return.